Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will work to develop targeted cancer treatments
September 5, 2013
By: Tim Wright
Editor-in-Chief, Contract Pharma
Almac Discovery and Queen’s University Belfast’s Centre for Cancer Research and Cell Biology (CCRCB) have launched a $20 million cancer drug discovery partnership to accelerate cancer-focused drug discovery in Northern Ireland. As part of the project, Queen’s and Almac have scheduled a Phase I clinical trial for ovarian cancer involving the first novel cancer drug fully developed in Northern Ireland. The drug was created as a result of an earlier collaboration between Almac Discovery and Professor Tracy Robson from the School of Pharmacy at Queen’s. Additionally, the Queen’s CCRCB and Almac entered a joint cancer drug discovery program that will work to identify parts of tumors that are susceptible to treatment by cancer drugs and to then develop the new drugs to target them. The partnership aims to enable new approaches to selecting patients that will be most likely to respond to the new drugs, and to create the technologies needed to deliver the drugs directly to the tumor site. Professor Robson said, “This latest trial involves a new treatment for cancer known as ALM201, which rather than attacking tumours directly, prevents the growth of new blood vessels in tumors, starving them of oxygen and nutrients and thereby preventing their growth. It targets tumours by an entirely different pathway to those treatments currently approved.” Alan Armstrong, chief executive officer of Almac said, “Bringing new treatments to patients is a complex process. The announcement today of a new clinical trial, which is the result of a previous partnership between Almac and Queen’s School of Pharmacy, is a timely illustration of how collaboration between the University and industry is already creating novel approaches to cancer therapy which have a very real chance of helping patients.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !